Nanocarrier vaccines for SARS-CoV-2

• Published in: Advanced drug delivery reviews 2021-04, Vol.171, p.215-239
• Main Authors: Machhi, Jatin, Shahjin, Farah, Das, Srijanee, Patel, Milankumar, Abdelmoaty, Mai Mohamed, Cohen, Jacob D., Singh, Preet Amol, Baldi, Ashish, Bajwa, Neha, Kumar, Raj, Vora, Lalit K., Patel, Tapan A., Oleynikov, Maxim D., Soni, Dhruvkumar, Yeapuri, Pravin, Mukadam, Insiya, Chakraborty, Rajashree, Saksena, Caroline G., Herskovitz, Jonathan, Hasan, Mahmudul, Oupicky, David, Das, Suvarthi, Donnelly, Ryan F., Hettie, Kenneth S., Chang, Linda, Gendelman, Howard E., Kevadiya, Bhavesh D.
• Format: Article
• Language: English
• Subjects: Animals; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Drug Carriers - administration & dosage; Drug Delivery Systems - methods; Drug Delivery Systems - trends; Humans; mRNA vaccine; Nanocapsules - administration & dosage; Nanovaccine; SARS-CoV-2; SARS-CoV-2 - drug effects; SARS-CoV-2 - immunology; Viral Vaccines - administration & dosage; Viral Vaccines - immunology
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2021.01.002

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery. [Display omitted]